Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Tocilizumab is a monoclonal antibody directed against the interleukin-6 receptor. It has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. In this observational study, patients with the syndrome who received tocilizumab had reduced mortality.

COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

A subset of patients with severe COVID-19 develops hyperinflammatory syndrome, which might contribute to morbidity and mortality. The study included 269 patients admitted to one of the study hospitals between March 1 and March 31, 2020.

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study

Hydroxychloroquine has received negative publicity for adverse events associated with its authorization for emergency use to treat patients with COVID-19 pneumonia. Long-term use of hydroxychloroquine appears to be associated with increased cardiovascular mortality. The addition of azithromycin appears to increase the risk of heart failure and chest pain or angina.

Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study

Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2. Overall mortality was lower in the hydroxychloroquine group than in the group that did not receive hydroxychloroquine.

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

Otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) This is a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcomes related to pain in patients with active rheumatoid arthritis.

MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study

Otilimab is a human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) This study was done at nine sites across the USA, Poland, and Germany. Otilimab was well tolerated and showed some evidence for improved synovitis over 12 weeks.

Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records

Biopsy length for diagnosis of giant cell arteritis is debated. We reviewed temporal artery biopsies from a 10-year period in Alberta to identify an ideal length. We suggest a 1.5 cm prefixation length is the optimal length for diagnosing giant cell arteritis.

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Severe COVID-19 is characterized by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a with the monoclonal antibody IFX-1.

Departments

Recent Posts